​

Q32 Bio (QTTB) Stock Forecast, Price Target & Predictions

OverviewFinancialsChart

QTTB Stock Forecast

Q32 Bio (QTTB) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $79.67, with a high of $95.00 and a low of $64.00. This represents a 2374.22% increase from the last price of $3.22.

- $19 $38 $57 $76 $95 High: $95 Avg: $79.67 Low: $64 Last Closed Price: $3.22

QTTB Stock Rating

Q32 Bio stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 1 Strong Buy (16.67%), 5 Buy (83.33%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 5 1 Strong Sell Sell Hold Buy Strong Buy

QTTB Forecast vs Benchmarks

TypeNameUpside
StockQ32 Bio2374.22%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts-17
Avg Price Target-$64.00$61.86
Last Closing Price$3.22$3.22$3.22
Upside/Downside-1887.58%1821.12%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25212--5
Dec, 24353--11
Nov, 2435---8
Oct, 2435---8
Sep, 2434---7
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024Etzer DaroutBMO Capital$64.00$23.69170.16%1887.58%
Oct 16, 2024Jay OlsonOppenheimer$80.00$48.4765.05%2384.47%
Sep 11, 2024Derek ArchilaWells Fargo$95.00$50.6187.71%2850.31%
May 21, 2024Thomas SmithLeerink Partners$54.00$30.2078.81%1577.02%
Apr 10, 2024Jay OlsonOppenheimer$50.00$21.48132.77%1452.80%
Apr 02, 2024Christopher RaymondRaymond James$45.00$18.00150.00%1297.52%
Apr 02, 2024Allison BratzelPiper Sandler$45.00$18.00150.00%1297.52%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Dec 05, 2024BMO CapitalOutperforminitialise
Oct 23, 2024Raymond JamesStrong Buyinitialise
Oct 16, 2024OppenheimerOutperformOutperformhold
Sep 11, 2024Wells FargoOverweightinitialise
Jun 17, 2024GuggenheimBuyinitialise
Apr 02, 2024Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-55 $-44 $-33 $-22 $-11 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-50.46$-0.17$-0.20$-35.16-----
Avg Forecast$-51.17$-30.06$-0.15$-35.64$-5.53$-4.14$-4.36$-5.53$-6.28
High Forecast$-51.17$-30.06$-0.15$-35.64$-5.67$-5.41$-4.36$-5.53$-6.28
Low Forecast$-51.17$-30.06$-0.15$-35.64$-5.33$-3.37$-4.36$-5.53$-6.28
Surprise %-1.39%-99.43%33.33%-1.35%-----

Revenue Forecast

$0 $11M $22M $33M $44M $55M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.70M$33.97M$6.65M$1.16M-----
Avg Forecast$2.90M$33.82M$2.95M$1.16M$2.00M$2.00M$2.00M$866.67K$54.59M
High Forecast$2.90M$33.82M$2.95M$1.16M$2.00M$2.00M$2.00M$866.67K$54.59M
Low Forecast$2.90M$33.82M$2.95M$1.16M$2.00M$2.00M$2.00M$866.67K$54.59M
Surprise %-6.80%0.44%125.23%------

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-128.69M$-37.56M$-42.81M$-112.96M-----
Avg Forecast$-164.40M$-96.58M$-477.33K$-114.51M$-17.75M$-13.29M$-14.00M$-17.76M$-20.19M
High Forecast$-164.40M$-96.58M$-477.33K$-114.51M$-18.20M$-17.39M$-14.00M$-17.76M$-20.19M
Low Forecast$-164.40M$-96.58M$-477.33K$-114.51M$-17.14M$-10.82M$-14.00M$-17.76M$-20.19M
Surprise %-21.72%-61.11%8868.43%-1.36%-----

QTTB Forecast FAQ

Is Q32 Bio stock a buy?

Q32 Bio stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 5 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Q32 Bio is a favorable investment for most analysts.

What is Q32 Bio's price target?

Q32 Bio's price target, set by 6 Wall Street analysts, averages $79.67 over the next 12 months. The price target range spans from $64 at the low end to $95 at the high end, suggesting a potential 2374.22% change from the previous close price of $3.22.

How does Q32 Bio stock forecast compare to the average forecast of its sector, industry, and investment themes?

Q32 Bio stock forecast shows a 2374.22% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Q32 Bio over the past three months?

  • January 2025: 40.00% Strong Buy, 20.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 27.27% Strong Buy, 45.45% Buy, 27.27% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 37.50% Strong Buy, 62.50% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Q32 Bio’s EPS forecast?

Q32 Bio's average annual EPS forecast for its fiscal year ending in December is -5.53 for 2024, a -84.27% decrease from the reported $-35.16 in 2023. The prediction for 2025 is $-4.14, $-4.36 for 2026, $-5.53 for 2027, and $-6.28 for 2028.

What is Q32 Bio’s revenue forecast?

Q32 Bio's average annual revenue forecast for its fiscal year ending in December is $2M for 2024, a 73.01% increase from the reported $1.16M in 2023. The forecast for 2025 is $2M, $2M for 2026, $866.67K for 2027, and $54.59M for 2028.

What is Q32 Bio’s net income forecast?

For its fiscal year ending in December, Q32 Bio's average annual net income forecast is $-17.752M for 2024, reflecting a -84.28% decrease from the reported $-113M in 2023. The projection for 2025 is $-13.287M, $-13.996M for 2026, $-17.76M for 2027, and $-20.186M for 2028.